This study is a randomized, parallel group clinical trial comparing the efficacy of AlbuminPrf and injectable Prf as an adjunct to scaling and root planing in the management of stage 2 periodontitis patients. In 2015, injectable platelet rich fibrin was developed and initially studied using a short, slow centrifugation protocol. This method allowed injectable PRF to remain in liquid form for approximately 15 to 20 minutes. The formulation was utilized in various procedures, including its combination with bone grafts to create a stable fibrin graft matrix, enhancing handling and graft stability. To address the stability limitations of platelet concentrates, a new process was introduced that involves combining the liquid portion of liquid PRF with denatured platelet poor plasma. This formulation was initially termed Albumin Concentrated albumin with the presence of a concentrate of growth factors, offering improved stability and extended clinical applicability.The process was later renamed AlbuminPRF albumin with liquid PRF.The incorporation of denatured serum albumin significantly strengthens the PRF based scaffold, resulting in an autologous, biocompatible material with improved stability and prolonged therapeutic effects.

Group 1: Albumin Prf after Scaling and root planing 

Group 2: injectable Prf after Scaling and root planing